Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
botulism antitoxin bivalent equine types a and b
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
Botulism antitoxin bivalent equine types A and B is a refined and concentrated preparation of antibody globulins obtained from horse (equine) plasma that has been immunized with botulinum toxin types A and B. The preparation consists of enzymatically digested immunoglobulins (mainly F(ab')₂ fragments), designed for passive immunization. It is indicated for the prevention and treatment of botulism caused by *Clostridium botulinum* toxin types A and B. Its mechanism is based on neutralizing circulating (unbound) botulinum neurotoxins in the bloodstream, thereby preventing their interaction with presynaptic cholinergic nerve endings and internalization into target cells. The product is administered via intravenous or intramuscular injection, with dosing depending on indication and patient characteristics. The drug is derived from equine sources, thus carries risk of hypersensitivity and serum sickness. The main developer and manufacturer was Sanofi Pasteur Limited[2].
- Other names
- botulism antitoxin type abbotulism antitoxin bivalent (equine)botulism antitoxin a and b (equine)botulinum antitoxin bivalent (equine) types a and b
02
Targets
BoNT/A (Botulinum neurotoxin type A)BoNT/B (Botulinum neurotoxin type B)
Beyond the preview
Go deeper on botulism antitoxin bivalent equine types a and b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on botulism antitoxin bivalent equine types a and b.